Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Natural Products in Health Promotion and Disease Prevention 2024
share announcement

Natural Products in Health Promotion and Disease Prevention 2024

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: 20 September 2024 | Viewed by 261

Special Issue Editors

Dr. Marco G. Alves

E-Mail Website1 Website2
Guest Editor
Institute of Biomedicine, Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal
Interests: metabolomics; cell metabolism; oxidative stress; mitochondria; sperm; spermatogenesis; cancer; antioxidants; obesity; diabetes; omics
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Ariane Zamoner

E-Mail Website
Guest Editor
Department of Biochemistry, Federal University of Santa Catarina, Florianópolis, SC, Brazil
Interests: redox mechanisms in biological systems; environmental toxicology and health; molecular mechanisms of disease; chemical stressor toxicity; reproductive endocrinology and toxicology; drug discovery and development; interdisciplinary approaches in biosciences
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Celebrating its 20th year, Pharmaceuticals is delighted to invite scientists to contribute articles and literature reviews on the impact and potential of natural products in health promotion and disease prevention. This Special Issue aims to explore the intersection between natural products and pharmaceutical science, highlighting recent discoveries and innovations. Natural products, encompassing a wide range of biological substances, have been used for health enhancement and disease treatment since ancient times. With the advancement of modern science, these products are being reevaluated, offering therapeutic benefits. This Special Issue seeks to gather research on the efficacy, safety, mechanisms of action and therapeutic potential of natural products. We are particularly interested in studies addressing the following themes: identification and characterization of new bioactive compounds; molecular mechanisms by which natural products influence health and disease; clinical studies testing the efficacy and safety of natural products; synergies between different natural compounds; and the regulatory and ethical implications of using natural products as nutraceuticals. This Special Issue is expected to provide a comprehensive and up-to-date overview of advancements in natural product research, encouraging discussion and collaboration among scientists, health professionals and policy-makers.

Dr. Marco Alves
Prof. Dr. Ariane Zamoner
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural products
  • nutraceuticals
  • bioactive compounds
  • traditional medicine
  • drug discovery

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 2975 KiB  
Article
Barbaloin Protects Pentylenetetrazol-Induced Cognitive Deficits in Rodents via Modulation of Neurotransmitters and Inhibition of Oxidative-Free-Radicals-Led Inflammation
by Ahmad Essam Altyar, Muhammad Afzal, Nehmat Ghaboura, Khalid Saad Alharbi, Sattam Khulaif Alenezi, Nadeem Sayyed and Imran Kazmi
Pharmaceuticals 2024, 17(6), 699; https://doi.org/10.3390/ph17060699 - 28 May 2024
Viewed by 82
Abstract
Background: Epilepsy is defined by an excessive level of activity in the neurons and coordinated bursts of electrical activity, resulting in the occurrence of seizure episodes. The precise cause of epileptogenesis remains uncertain; nevertheless, the etiology of epilepsy may involve neuroinflammation, oxidative stress, [...] Read more.
Background: Epilepsy is defined by an excessive level of activity in the neurons and coordinated bursts of electrical activity, resulting in the occurrence of seizure episodes. The precise cause of epileptogenesis remains uncertain; nevertheless, the etiology of epilepsy may involve neuroinflammation, oxidative stress, and malfunction of the neurotransmitter system. Objective: The goal of this investigation was to assess barbaloin’s protective properties with respect to pentylenetetrazol (PTZ)-)-induced cognitive deficits in rats via antioxidative, anti-inflammatory, and neurotransmitter-modulating effects. Methods: Wistar rats were subjected to PTZ [40 mg/kg (i.p.)], which induced cognitive decline. Behavior assessment using a kindling score, open-field test (OFT), novel object recognition test (NORT), and assays for superoxide dismutase (SOD), reduced glutathione (GSH), catalase (CAT), malondialdehyde (MDA), acetylcholinesterase (AChE), caspase-3, nitric oxide (NO), interleukins-1β (IL-1β), tumor necrosis factor-α (TNF-α), IL-6, nuclear factor kappa-B (NF-κB), Bcl-2 and Bax, and neurotransmitter levels [GABA, DA, NE, and serotonin (5-HT)] were performed. Results: The treatment of rats with barbaloin resulted in behavior improvement and significant changes in the levels of GSH, SOD, CAT, MDA, AChE, NO, IL-6, IL-1β, TNF-α, NF-κB, caspase-3, Bcl-2, and Bax compared to the PTZ control group. Barbaloin treatment resulted in notable changes in neurotransmitter levels (GABA, NE, 5-HT, DA) compared to the PTZ group. Conclusions: The ongoing study has gathered evidence indicating that the injection of barbaloin has resulted in significant improvements in cognitive performance in rats. This is achieved by inhibiting oxidative stress, enhancing the activity of natural antioxidant enzymes, reducing cytokine levels, and increasing the levels of neurotransmitters in the brain. These results were detected in comparison to a PTZ control and can be attributed to the potent anti-inflammatory and antioxidant capabilities of barbaloin, which could be linked to its neuroprotective properties. Barbaloin may potentially increase cognitive decline and boost neuronal survival by altering the expression of Bax, caspase-3, Bcl-2. Full article
(This article belongs to the Special Issue Natural Products in Health Promotion and Disease Prevention 2024)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop